F-star Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following press release that they use animals for product testing.
“In preclinical studies, FS222-mediated PD-L1 blockade that synergized with conditional CD137 agonism stimulated lymphocyte activation and showed antitumor responses beyond that achieved with PD-L1 inhibition alone. FS222 is Fcg receptor null and was well tolerated in preclinical toxicology studies using animal models.” Read the following article
F-Star Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immunotherapies to transform the lives of patients with cancer. The Company’s FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
Company Website: https://f-star.com